for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Xencor Inc

XNCR.OQ

Latest Trade

36.91USD

Change

1.43(+4.03%)

Volume

688,775

Today's Range

35.28

 - 

37.44

52 Week Range

27.75

 - 

46.33

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
35.48
Open
35.49
Volume
688,775
3M AVG Volume
12.59
Today's High
37.44
Today's Low
35.28
52 Week High
46.33
52 Week Low
27.75
Shares Out (MIL)
56.62
Market Cap (MIL)
2,089.85
Forward P/E
1,175.48
Dividend (Yield %)
--

Next Event

Xencor Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Xencor Posts Q2 Loss Per Share Of $0.28

Xencor Reports Q1 Earnings Per Share $1.38

Xencor And Astellas Enter Collaboration For Novel Bispecific Antibody Program

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.

Industry

Biotechnology & Drugs

Contact Info

111 W Lemon Ave

+1.626.3055900

http://www.xencor.com/

Executive Leadership

Bassil I. Dahiyat

President, Chief Executive Officer, Founder and Director

John R. Desjarlais

Senior Vice President, Research and Chief Scientific Officer

Paul Foster

Senior Vice President and Chief Medical Officer

John J. Kuch

Vice President - Finance

Celia Eckert

Vice President, General Counsel, Corporate Secretary

Key Stats

2.00 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (USD)

2016

0.560

2017

-1.050

2018

-1.310

2019(E)

0.031
Price To Earnings (TTM)
44.67
Price To Sales (TTM)
12.15
Price To Book (MRQ)
3.43
Price To Cash Flow (TTM)
39.68
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
8.58
Return on Equity (TTM)
7.67

Latest News

CORRECTED-BRIEF-Marketaxess Holdings Set To Join S&P 500

* MARKETAXESS HOLDINGS SET TO JOIN S&P 500; AXON ENTERPRISE TO JOIN S&P MIDCAP 400; OTHERS TO JOIN S&P SMALLCAP 600

BRIEF-Xencor To Develop, Commercialize Il-15 Immune Activating Cytokines With Roche's Genentech

* XENCOR TO DEVELOP AND COMMERCIALIZE NOVEL IL-15 IMMUNE ACTIVATING CYTOKINES WITH GENENTECH

BRIEF-Xencor Regains Ex-U.S. Commercial Rights To Xmab®13676, Cd20 X Cd3 Bispecific Antibody

* XENCOR REGAINS EX-U.S. COMMERCIAL RIGHTS TO XMAB®13676, CD20 X CD3 BISPECIFIC ANTIBODY

BRIEF-Xencor Reports Q1 Loss Per Share $0.62

* Q1 EARNINGS PER SHARE VIEW $-0.46 -- THOMSON REUTERS I/B/E/S

BRIEF-Xencor Says Public Offering Of 7.30 Mln Common Shares Priced At $31 Per Share

* XENCOR ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Xencor Files For Potential Mixed Shelf Offering

* XENCOR INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING Source text: (http://bit.ly/2G8MdV1) Further company coverage:

BRIEF-Xencor Announces Proposed Public Offering Of Common Stock

* XENCOR, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Xencor Reports Q4 Loss Per Share $0.25

* XENCOR REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Xencor Doses First Patient In Phase 1 Study Of Xmab®18087,An Antibody For Treatment Of Neuroendocrine Tumors And Gastrointestinal Stromal Tumors

* XENCOR DOSES FIRST PATIENT IN PHASE 1 STUDY OF XMAB®18087 BISPECIFIC TUMOR TARGETING ANTIBODY FOR THE TREATMENT OF NEUROENDOCRINE TUMORS AND GASTROINTESTINAL STROMAL TUMORS

BRIEF-Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus

* XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB®5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS

BRIEF-Xencor Receives Milestone Payment From Amgen

* SAYS IT HAS EARNED A $10 MILLION MILESTONE PAYMENT FROM AMGEN

BRIEF-Xencor posts Q3 loss of $0.33 per share

* Xencor reports third quarter 2017 financial results and provides clinical pipeline update

BRIEF-Xencor Q2 loss per share $0.15

* Qtrly earnings per share $0.15 Source text for Eikon: Further company coverage:

BRIEF-Xencor reports interim positive data from ongoing mid-stage study of XMAB5871

* Xencor presents interim data from an ongoing, open-label, phase 2 study of xmab®5871 in igg4-related disease at eular 2017

BRIEF-Xencor's lead drug candidate receives orphan drug designation from FDA

* Xencor's lead drug candidate, xmab5871, receives orphan drug designation from fda for treatment of igg4-related disease Source text for Eikon: Further company coverage:

BRIEF-Xencor reports Q1 loss per share $0.31

* Q1 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S

BRIEF-Xencor reports qtrly loss per share $0.21

* Based on current operating plans, xencor expects to have cash to fund research and development programs and operations beyond end of 2020

BRIEF-Xencor posts Q3 loss per share $0.20

* Q3 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S

BRIEF-Xencor inc files for mixed shelf of upto $300 million

* Files for mixed shelf of upto $300 million - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Xencor doses first patient in blood cancer test

* Oncology bispecific program XmAb14045 for the treatment of acute myeloid leukemia and other CD123-expressing hematologic malignancies

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up